RetractedArticleCancer chemotherapy and pharmacology2022

Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.

Mototsugu Oya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.